{"result": {"id": "4928f7d9-aa06-4ce7-a4ca-b860f86ce4b4", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>中国高血压患者血压血脂综合管理的专家共识<|>EVENT<|>An expert consensus on comprehensive management of blood pressure and lipids in Chinese hypertensive patients\")  \n##\n(\"entity\"<|>中国成人动脉粥样硬化性心血管疾病基层管理路径专家共识<|>EVENT<|>An expert consensus on the management of atherosclerotic cardiovascular disease in Chinese adults\")  \n##\n(\"entity\"<|>Anglo-Scandinavian Cardiac Outcomes Trial: lipid Lowering Arm (ASCOT-LLA)<|>EVENT<|>A multicentre randomised controlled trial studying atorvastatin in hypertensive patients\")  \n##\n(\"entity\"<|>ASTEROID trial<|>EVENT<|>A clinical trial studying the effects of cholesterol reduction on coronary atheroma\")  \n##\n(\"entity\"<|>ST段抬高型心肌梗死基层合理用药指南<|>EVENT<|>Guidelines for the rational use of drugs in ST-segment elevation myocardial infarction at the primary care level\")  \n##\n(\"entity\"<|>稳定性冠心病基层合理用药指南<|>EVENT<|>Guidelines for the rational use of drugs in stable coronary heart disease at the primary care level\")  \n##\n(\"entity\"<|>动脉粥样硬化性缺血性卒中/短暂性脑缺血发作合并冠心病诊治中国专家共识<|>EVENT<|>Chinese expert consensus on the diagnosis and treatment of atherosclerotic ischemic stroke/TIA combined with coronary heart disease\")  \n##\n(\"entity\"<|>中国<|>GEO<|>Country where the medical research and consensus documents were produced\")  \n##\n(\"entity\"<|>北京<|>GEO<|>Location of the Beijing Neuroscience Society\")  \n##\n(\"relationship\"<|>学分会高血压学组<|>中国高血压患者血压血脂综合管理的专家共识<|>The 学分会高血压学组 contributed to the expert consensus on hypertension management<|>8)  \n##\n(\"relationship\"<|>中华心血管病杂志编辑委员会<|>中国高血压患者血压血脂综合管理的专家共识<|>The 中华心血管病杂志编辑委员会 published the expert consensus<|>8)  \n##\n(\"relationship\"<|>李玉明<|>中国高血压患者血压血脂综合管理的专家共识<|>李玉明 contributed to the expert consensus<|>7)  \n##\n(\"relationship\"<|>曾益新<|>中国成人动脉粥样硬化性心血管疾病基层管理路径专家共识<|>曾益新 contributed to the expert consensus<|>7)  \n##\n(\"relationship\"<|>祝墡珠<|>中国成人动脉粥样硬化性心血管疾病基层管理路径专家共识<|>祝墡珠 contributed to the expert consensus<|>7)  \n##\n(\"relationship\"<|>于晓松<|>中国成人动脉粥样硬化性心血管疾病基层管理路径专家共识<|>于晓松 contributed to the expert consensus<|>7)  \n##\n(\"relationship\"<|>SEVER PS<|>Anglo-Scandinavian Cardiac Outcomes Trial: lipid Lowering Arm (ASCOT-LLA)<|>SEVER PS was a researcher in the ASCOT-LLA trial<|>9)  \n##\n(\"relationship\"<|>DAHL?F B<|>Anglo-Scandinavian Cardiac Outcomes Trial: lipid Lowering Arm (ASCOT-LLA)<|>DAHL?F B was a researcher in the ASCOT-LLA trial<|>9)  \n##\n(\"relationship\"<|>POULTER NR<|>Anglo-Scandinavian Cardiac Outcomes Trial: lipid Lowering Arm (ASCOT-LLA)<|>POULTER NR was a researcher in the ASCOT-LLA trial<|>9)  \n##\n(\"relationship\"<|>GRATSIANSKI? NA<|>ASTEROID trial<|>GRATSIANSKI? NA was involved in the ASTEROID trial<|>9)  \n##\n(\"relationship\"<|>中华医学会<|>ST段抬高型心肌梗死基层合理用药指南<|>中华医学会 published the guidelines<|>8)  \n##\n(\"relationship\"<|>中华医学会临床药学分会<|>ST段抬高型心肌梗死基层合理用药指南<|>中华医学会临床药学分会 contributed to the guidelines<|>8)  \n##\n(\"relationship\"<|>中华医学会杂志社<|>ST段抬高型心肌梗死基层合理用药指南<|>中华医学会杂志社 published the guidelines<|>8)  \n##\n(\"relationship\"<|>中华医学会<|>稳定性冠心病基层合理用药指南<|>中华医学会 published the guidelines<|>8)  \n##\n(\"relationship\"<|>中华医学会临床药学分会<|>稳定性冠心病基层合理用药指南<|>中华医学会临床药学分会 contributed to the guidelines<|>8)  \n##\n(\"relationship\"<|>中华医学会杂志社<|>稳定性冠心病基层合理用药指南<|>中华医学会杂志社 published the guidelines<|>8)  \n##\n(\"relationship\"<|>中华医学会老年医学分会老年神经病学组<|>动脉粥样硬化性缺血性卒中/短暂性脑缺血发作合并冠心病诊治中国专家共识<|>The group contributed to the expert consensus<|>8)  \n##\n(\"relationship\"<|>北京神经科学学会血管神经病学专业委员会<|>动脉粥样硬化性缺血性卒中/短暂性脑缺血发作合并冠心病诊治中国专家共识<|>The committee contributed to the expert consensus<|>8)  \n##\n(\"relationship\"<|>动脉粥样硬化性缺血性卒中/短暂性脑缺血发作合并冠心病诊治中国专家共识编写组<|>动脉粥样硬化性缺血性卒中/短暂性脑缺血发作合并冠心病诊治中国专家共识<|>The writing group drafted the expert consensus<|>9)  \n##\n(\"relationship\"<|>代爽<|>中国<|>代爽 conducted research in China<|>5)  \n##\n(\"relationship\"<|>何庆勇<|>中国<|>何庆勇 conducted research in China<|>5)  \n##\n(\"relationship\"<|>杨戈<|>中国<|>杨戈 conducted research in China<|>5)  \n##\n(\"relationship\"<|>北京神经科学学会血管神经病学专业委员会<|>北京<|>The committee is based in Beijing<|>7)  \n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752165791, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 1372, "prompt_tokens": 4294, "total_tokens": 5666, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 4224}, "prompt_cache_hit_tokens": 4224, "prompt_cache_miss_tokens": 70}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 学分会高血压学组，中华心血管病杂志编 辑委员会，李玉明，等 . 中国高血压患者血压血脂综合管理的 专家共识［J］. 中华心血管病杂志，2021，49（6）：554-563.\n［30］ 曾益新，祝墡珠，于晓松，等 . 中国成人动脉粥样硬化性心血 管疾病基层管理路径专家共识（建议稿）［J］. 中国全科医学， 2017，20（3）：251-261.\n\n\n［31］ SEVER PS，DAHL?F B，POULTER NR，et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than- average cholesterol concentrations，in the Anglo- Scandinavian Cardiac Outcomes Trial：lipid Lowering Arm（ASCOT-LLA）：a multicentre randomised controlled trial［J］. Lancet，2003，361（9364）：1149-1158.\n［32］ 范利 . 钙离子拮抗剂和β受体阻滞剂的抗动脉粥样硬化作用 ［J］. 中华老年医学杂志，2007，26（10）：741-743.\n［33］ 陈源源，王增武，李建军，等 . 高血压患者血压血脂综合管 理 中 国 专家 共识［J］ . 中华 高 血压 杂 志，2019，27（7）： 605-614.\n［34］ 基层卫生健康司 . 关于做好 2014 年国家基本公共卫生服务项目 工 作 的 通 知 ［EB/OL］ .（2014-10-08）. http：//www.nhc. gov.cn/jws/zcwj/201409/acaeab089ac44d7a87d38393ccec 4a78.shtml.\n［35］ FERRIER KE，MUHLMANN MH，BAGUET JP，et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension［J］. JAm Coll Cardiol，2002，39（6）：1020-1025.\n［36］ GRATSIANSKI? NA.Pronounced lowering of low density cholesterol combined with elevation of high density cholesterol was associated with reduction of coronary atheroma.Results of ASTEROID trial［J］. Kardiologiia， 2006，46（5）：71-73.\n［37］ 中华医学会，中华医学会临床药学分会，中华医学会杂志社， 等 .ST 段抬高型心肌梗死基层合理用药指南［J］. 中华全科医 师杂志，2021，20（4）：397-409.\n［38］ 中华医学会，中华医学会临床药学分会，中华医学会杂志社， 等 . 稳定性冠心病基层合理用药指南［J］. 中华全科医师杂志， 2021，20（4）：423-434.\n［39］ 中华医学会老年医学分会老年神经病学组，北京神经科学学会 血管神经病学专业委员会，动脉粥样硬化性缺血性卒中/短暂性 脑缺血发作合并冠心病诊治中国专家共识编写组 . 动脉粥样硬 化性缺血性卒中/短暂性脑缺血发作合并冠心病诊治中国专家 共识（2022）［J］. 中华 医学杂志，2022，102（45）：3569- 3580.\n［40］ 代爽，何庆勇，杨戈，等 . 基于对应分析探讨血脂异常患者中 医证候与合并病的相关性［J］. 中华中医药杂志，2022，37\n（2）：1141-1144.\n［41］ �\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>学分会高血压学组<|>ORGANIZATION<|>A group focused on hypertension research and management in China\")  \n##\n(\"entity\"<|>中华心血管病杂志编辑委员会<|>ORGANIZATION<|>Editorial board of the Chinese Journal of Cardiovascular Diseases, responsible for publishing expert consensus on hypertension and cardiovascular health\")  \n##\n(\"entity\"<|>李玉明<|>PERSON<|>A contributor to the expert consensus on comprehensive management of blood pressure and lipids in Chinese hypertensive patients\")  \n##\n(\"entity\"<|>曾益新<|>PERSON<|>A contributor to the expert consensus on the management of atherosclerotic cardiovascular disease in Chinese adults\")  \n##\n(\"entity\"<|>祝墡珠<|>PERSON<|>A contributor to the expert consensus on the management of atherosclerotic cardiovascular disease in Chinese adults\")  \n##\n(\"entity\"<|>于晓松<|>PERSON<|>A contributor to the expert consensus on the management of atherosclerotic cardiovascular disease in Chinese adults\")  \n##\n(\"entity\"<|>SEVER PS<|>PERSON<|>A researcher involved in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-LLA) studying atorvastatin in hypertensive patients\")  \n##\n(\"entity\"<|>DAHL?F B<|>PERSON<|>A researcher involved in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-LLA) studying atorvastatin in hypertensive patients\")  \n##\n(\"entity\"<|>POULTER NR<|>PERSON<|>A researcher involved in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-LLA) studying atorvastatin in hypertensive patients\")  \n##\n(\"entity\"<|>范利<|>PERSON<|>A researcher studying the anti-atherosclerotic effects of calcium ion antagonists and beta-blockers\")  \n##\n(\"entity\"<|>陈源源<|>PERSON<|>A contributor to the expert consensus on comprehensive management of blood pressure and lipids in Chinese hypertensive patients\")  \n##\n(\"entity\"<|>王增武<|>PERSON<|>A contributor to the expert consensus on comprehensive management of blood pressure and lipids in Chinese hypertensive patients\")  \n##\n(\"entity\"<|>李建军<|>PERSON<|>A contributor to the expert consensus on comprehensive management of blood pressure and lipids in Chinese hypertensive patients\")  \n##\n(\"entity\"<|>基层卫生健康司<|>ORGANIZATION<|>A department responsible for national basic public health service projects in China\")  \n##\n(\"entity\"<|>FERRIER KE<|>PERSON<|>A researcher studying the effects of intensive cholesterol reduction on blood pressure and arterial stiffness\")  \n##\n(\"entity\"<|>MUHLMANN MH<|>PERSON<|>A researcher studying the effects of intensive cholesterol reduction on blood pressure and arterial stiffness\")  \n##\n(\"entity\"<|>BAGUET JP<|>PERSON<|>A researcher studying the effects of intensive cholesterol reduction on blood pressure and arterial stiffness\")  \n##\n(\"entity\"<|>GRATSIANSKI? NA<|>PERSON<|>A researcher involved in the ASTEROID trial studying the effects of cholesterol reduction on coronary atheroma\")  \n##\n(\"entity\"<|>中华医学会<|>ORGANIZATION<|>Chinese Medical Association, involved in publishing guidelines for the management of cardiovascular diseases\")  \n##\n(\"entity\"<|>中华医学会临床药学分会<|>ORGANIZATION<|>A branch of the Chinese Medical Association focused on clinical pharmacy\")  \n##\n(\"entity\"<|>中华医学会杂志社<|>ORGANIZATION<|>Publishing arm of the Chinese Medical Association, responsible for medical journals\")  \n##\n(\"entity\"<|>中华医学会老年医学分会老年神经病学组<|>ORGANIZATION<|>A group under the Chinese Medical Association focused on geriatric neurology\")  \n##\n(\"entity\"<|>北京神经科学学会血管神经病学专业委员会<|>ORGANIZATION<|>A committee under the Beijing Neuroscience Society focused on vascular neurology\")  \n##\n(\"entity\"<|>动脉粥样硬化性缺血性卒中/短暂性脑缺血发作合并冠心病诊治中国专家共识编写组<|>ORGANIZATION<|>A group responsible for drafting the Chinese expert consensus on the diagnosis and treatment of atherosclerotic ischemic stroke/TIA combined with coronary heart disease\")  \n##\n(\"entity\"<|>代爽<|>PERSON<|>A researcher studying the correlation between traditional Chinese medicine syndromes and comorbidities in patients with dyslipidemia\")  \n##\n(\"entity\"<|>何庆勇<|>PERSON<|>A researcher studying the correlation between traditional Chinese medicine syndromes and comorbidities in patients with dyslipidemia\")  \n##\n(\"entity\"<|>杨戈<|>PERSON<|>A researcher studying the correlation between traditional Chinese medicine syndromes and comorbidities in patients with dyslipidemia\")  \n##\n(\"relationship\"<|>李玉明<|>学分会高血压学组<|>李玉明 is associated with the 学分会高血压学组 as a contributor to their expert consensus<|>7)  \n##\n(\"relationship\"<|>李玉明<|>中华心血管病杂志编辑委员会<|>李玉明 contributed to a publication by the 中华心血管病杂志编辑委员会<|>6)  \n##\n(\"relationship\"<|>曾益新<|>祝墡珠<|>曾益新 and 祝墡珠 co-authored an expert consensus on atherosclerotic cardiovascular disease management<|>5)  \n##\n(\"relationship\"<|>曾益新<|>于晓松<|>曾益新 and 于晓松 co-authored an expert consensus on atherosclerotic cardiovascular disease management<|>5)  \n##\n(\"relationship\"<|>SEVER PS<|>DAHL?F B<|>SEVER PS and DAHL?F B collaborated on the ASCOT-LLA trial<|>8)  \n##\n(\"relationship\"<|>SEVER PS<|>POULTER NR<|>SEVER PS and POULTER NR collaborated on the ASCOT-LLA trial<|>8)  \n##\n(\"relationship\"<|>陈源源<|>王增武<|>陈源源 and 王增武 co-authored an expert consensus on hypertension management<|>6)  \n##\n(\"relationship\"<|>陈源源<|>李建军<|>陈源源 and 李建军 co-authored an expert consensus on hypertension management<|>6)  \n##\n(\"relationship\"<|>FERRIER KE<|>MUHLMANN MH<|>FERRIER KE and MUHLMANN MH collaborated on research about cholesterol reduction and blood pressure<|>7)  \n##\n(\"relationship\"<|>FERRIER KE<|>BAGUET JP<|>FERRIER KE and BAGUET JP collaborated on research about cholesterol reduction and blood pressure<|>7)  \n##\n(\"relationship\"<|>中华医学会<|>中华医学会临床药学分会<|>中华医学会临床药学分会 is a branch of the 中华医学会<|>9)  \n##\n(\"relationship\"<|>中华医学会<|>中华医学会杂志社<|>中华医学会杂志社 is affiliated with the 中华医学会<|>9)  \n##\n(\"relationship\"<|>代爽<|>何庆勇<|>代爽 and 何庆勇 collaborated on research about dyslipidemia and traditional Chinese medicine<|>6)  \n##\n(\"relationship\"<|>代爽<|>杨戈<|>代爽 and 杨戈 collaborated on research about dyslipidemia and traditional Chinese medicine<|>6)  \n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_1603b90689383b231ef164d7ced1b36fc3af2818b4838214bc7c6efd385b8edd_v2"}